Previous 10 | Next 10 |
SOURCE: MorphoSys AG View source version on accesswire.com: https://www.accesswire.com/634512/Invitation-to-MorphoSys-Full-Year-Results-2020-Conference-Call-on-March-16-2021
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / March 2, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody, protein and peptide technologies, announced today that its licensing partner GlaxoSmith...
SOURCE: MorphoSys AG View source version on accesswire.com: https://www.accesswire.com/632807/Morphosys-AG-Preliminary-Results-for-the-Fiscal-Year-2020-Exceeding-Guidance
Adagene completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading. Nuance Pharma in-licensed Greater China rights to a late-stage candidate for osteoarthritis pain from Antibe Therapeutics in a $100 million agreement. Junshi Biosciences and Eli Lilly announ...
I-Mab ([[IMAB]] +8.5%) announced that it received regulatory approval in China to initiate Phase 1 trial for TJ210/MOR210 monotherapy in patients with advanced solid tumors.With the approval received from Center for Drug Evaluation (“CDE”) of the China National Medical...
PLANEGG/MUNICH, GERMANY and SHANGHAI, CHINA / ACCESSWIRE / January 25, 2021 / MorphoSys (FSE:MOR)(Prime Standard Segment, MDAX & TecDAX)(NASDAQ:MOR) and I-Mab (IMAB) today announced that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerabil...
I-Mab (IMAB) and MorphoSys (MOR) announce that the first patient has been dosed in a phase 1 dose escalation study to evaluate the safety, tolerability, pharmacokinetics ((PK)) and pharmacodynamics ((PD)) of TJ210/MOR210 monotherapy in patients with relapsed or refractory advanced solid tumor...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Optimism over a return to normal economic activity global...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. 2020 was a year of monumental progress in renewable energ...
The following slide deck was published by MorphoSys AG in conjunction with this event. For further details see: MorphoSys AG (MOR) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
News, Short Squeeze, Breakout and More Instantly...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that it has formally notified the Nasdaq Stock Market of its intention to voluntarily delist its American Depositary Shares (“ADSs”) from the Nasdaq Global Market and to deregister the ADSs under Section 12(b) of the Securities Ex...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024. Novartis BidCo Germany AG (together with Novartis BidCo AG ...
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...